Summary
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.
Register to download
PRA Successfully Rescues Phase II Hematology Study
You may also be interested in:
Webcast
The Challenges of Patient Recruitment in Oncology Trials - Part 3
A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical…
View Resource
Blog
World Blood Donor Day 2020: Why is Donating Blood Important, Especially During a Pandemic?
To mark World Blood Donor Day, we interviewed two members of our PRA family who have gone above and beyond for Red Cross efforts. We discussed why…
Read Story
Blog
What does the Future Hold for Stomach, Lung, and Testicular Cancer Treatments?
Cancer is a leading cause of death worldwide. Despite the lack of a definitive cure for cancer, there are many types of cancer treatments. A…
Read Story
View all related content and resources for Hematology
Explore Insights